Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or in combination are clinically used for this disorder. To assess the efficacy and safety of combined Alfuzosin plus Finasteride, in patients with LUTS due to BHP. Methods: In this hospital-based, Quasi-experimental study (One-Group Pre test-Post test Design) without Control Groups, 30 consecutive patients were selected as per set criteria for medical management of BPH with combination of 10mg Alfuzosin and 5mg Finasteride, for 12-months, in the outpatient Department of Urology, in Chittagong Medical College Hospital. The primary efficacy criteria were improvement in symptoms (International Prostate Symptom Score (IPSS) peak urinary flow rate and reduction of prostate volume from baseline. Results: Combination therapy with Alfuzosin plus Finasteride was effective in improving the symptoms and peak urinary flow rate from the first follow-up visit (Day 90) in comparison to baseline score. The mean change in the IPSS from baseline at endpoint was 10±1.87 (p=0.001). The percentage increase in the peak urinary flow rate was 4.8 mL/s, compared with 11.0±1.82 mL/s at baseline (p=0.001). The patients' quality of life also significantly improved. The percentage decrease in prostate volume at end point was 15.13±11.3 cc (p=0.001). Overall, this combination therapy was well tolerated. The incidence of orthostatic hypotension as determined by systematic blood pressure measurements was only 3(10%). No clinically relevant ejaculation disorders were observed. Conclusion: Alfuzosin plus Finasteride provides effective relief from the symptoms of benign prostatic hyperplasia by reducing the size of the prostate. It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation.Key words: BPH; Alfuzosin; Finasteride; IPSS; Qmax; PVR. INTRODUCTIONBenign Prostatic Hyperplasia (BPH) is characterized by Lower Urinary Tract Symptoms (LUTS) urinary frequency, urgency, a weak and intermittent stream needing to strain, a sense of incomplete emptying, and nocturia), and can lead to complications, including acute urinary retention 1, 2 . BPH is common among older men, with approximately 25% of men over 40 3 . The treatment of symptomatic BPH focuses on relieving the bothersome and irritative symptoms that negatively affect patients' quality of life and inhibiting the clinical progression of the disease.

Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or combined are clinically used for this disorder. This study was aimed to evaluate the efficacy and safety of Alfuzosin monotherapy versus combination of Alfuzosin and Finasteride in treatment of LUTS due to BPH. Materials and methods: This clinical trial was conducted in the outpatient Department of Urology Chittagong Medical College Hospital from May 2007 to October 2008. After assessing for the eligibility, consecutive consenting 60 patients with LUTS related to BPH were randomly assigned to either 10mg Alfuzosin (Group A) or combination of 10mg Alfuzosin and 5mg Finasteride (Group B) for 12 months. The response was assessed by measurements of International Prostate Symptoms Score (IPSS) Maximum urine flow rate (Qmax), Post Voidal Residual Volume (PVR) and prostate volume at baseline and 3 monthly thereafter. Safety was assessed by Adverse Drug Events (ADE) rate. Results: Both Groups showed comparable significant improvements in all parameters in terms of decreasing IPSS, PVR and increasing Qmax. Both treatments were well tolerated with respect to ADE and distribution of ADE was similar in two groups. Conclusion: In men with benign prostatic hyperplasia, Alfuzosin was effective therapy and the combination of Alfuzosin and Finasteride was no more effective than Alfuzosin alone. JCMCTA 2017 ; 28 (2) : 75-80